Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: Identification of rapidly progressive and chronic subtypes
Bjarni A. Agnarsson(Reykjavík University), Marshall E. Kadin(University of Minnesota), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust)
Cited by 206
Related Papers
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
|New England Journal of Medicine|1987|1.2k
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes
|Nature Genetics|2007|725
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610